NBTC was established in 2021 supported by a basic grant funding from the Norwegian Cancer Society through the funding initiative Krafttak mot kreft. NBTC has also received financial support from the Norwegian Brain Tumor Association. The prerequisite for the establishment of NBTC was that leading Norwegian researchers and clinicians work together, in collaboration towards achieving key common goals, where research data, knowledge and expertise are shared. This approach will enable an increased level of collaboration on clinical studies both at a national and international level with the aim to offer new and experimental treatment to brain tumor patients.
Board of directors in the consortium
The board of directors in the consortium consist of two members from each institution.